Clinical Outcomes of 2Nd- and 3Rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Kensuke Naruto,Tomokazu Kawaoka,Kei Amioka,Yutaro Ogawa,Kikukawa Chihiro,Yuki Yoshikawa,Yuwa Ando,Yosuke Suehiro,Yumi Kosaka,Shinsuke Uchikawa,Kenichiro Kodama,Kei Morio,Hatsue Fujino,Eisuke Murakami,Takashi Nakahara,Masami Yamauchi,Masataka Tsuge,Akira Hiramatsu,Takayuki Fukuhara,Shintaro Takaki,Nami Mori,Keiji Tsuji,Michihiro Nonaka,Hideyuki Hyogo,Yasuyuki Aisaka,Keiichi Masaki,Yoji Honda,Hirotaka Kohno,Hiroshi Kohno,Takashi Moriya,Noriaki Naeshiro,Takahiro Azakami,Michio Imamura,Kazuaki Chayama,Hiroshi Aikata Oncology（2021）
Key words
Regorafenib,Hepatocellular carcinoma,3rd line
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper